About META Pharmaceuticals

Founded by scientists from Weill Cornell Medicine, META Pharmaceuticals is a clinical-stage Biotech pioneering First-in-class therapies for autoimmune diseases. Its lead asset, MP-5342, enters clinical trials in H2 2026 alongside AI-driven discovery partnerships with XtalPi (2228.HK).

Our Role & Solutions by SUMA Design

To fulfill META's rigorous standards for scientific accuracy and international brand optics during review:

• Interactive MOA & Sequence Motion: Built custom sequence animations and an interactive "balancing scale" UI to visually demonstrate MP-5342's mechanism in restoring immune homeostasis.

• Custom 3D Rendered Icons & UI: Designed bespoke 3D-rendered icon systems strictly aligned with brand VI, elevating site aesthetics with modern depth.

• R&D Pipeline & AI Showcase: Restructured clinical roadmaps to build high-trust engagement for global investors.

• High-Performance Frontend: Lightweight architecture and async asset loading ensure smooth, zero-friction rendering across all key modules.